ESR1 and breast cancer: In this patient group, adjuvant BPs produced highly significant reductions in bone recurrence (RR 0.72, 95% CI 0.60–0.86; 2p=0.0002) and breast cancer mortality (RR 0.82, 0.73–0.93; 2p=0.002).These effects were independent of tumor parameters (estrogen receptor status or grade), nodal status, bisphosphonate class, or dosing schedule or concomitant chemotherapy [23, 26].